A Phase 2 Study Evaluating Taldefgrobep, a Novel Myostatin/Activin Pathway Inhibitor, in Obesity (OBESITY WEEK 2026) - Oct 12, 2026 - Pres time: Nov 14, 2026; 07:30 PM - 08:30 PM; Location: Gaylord National Resort & Convention Ctr: Exhibit Hall BCD; No abstract available
P2 data • Genetic Disorders • Obesity
|